Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Cytokine1 who wrote (4873)	5/12/1998 11:48:00 AM
From: Vector1	Respond to of 9719

Cyto, More good news on CLTR. PALO ALTO, Calif. (Dow Jones)--Coulter Pharmaceutical Inc. (CLTR) said interim data from its Phase III trial of Bexxar show that 10 of 22 patients responded to the drug for a longer period of time than their prior chemotherapy. In a press release Tuesday, Coulter said nine patients responded to both treatments for equal amounts of time. The trial tested Bexxar on 30 patients with non-Hodgkin's lymphoma cancer. 22 had adequate follow-up data. Nasdaq-listed share of Coulter Pharmaceutical were trading up 1 7/8 or 6%, at 33 1/4 on volume of 290,900 shares. Average daily composite volume is 110,013 shares. The primary goal of the trial is to prove that patients will respond to Bexxar for at least one month longer than chemotherapy in a significant number of patients. A second Phase III trial is testing 60 patients who had no response to chemotherapy. Coulter develops drugs and therapies for cancer treatment. (END) DOW JONES NEWS 05-12-98 10:12 AM Additional Codes (R/US, R/USW)